Press release

Release
17.07.2020

VALBIOTIS opens up its capital to a new shareholder: AMIRAL GESTION

Download
Release
15.07.2020

VALBIOTIS announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study on TOTUM-63 to reduce Type 2 Diabetes risk factors

Download
Release
08.07.2020

VALBIOTIS: authorization to launch the international Phase II/III REVERSE-IT clinical study on TOTUM-63, to reduce Type 2 Diabetes risk factors

Download
Release
12.06.2020

VALBIOTIS selected at the 80th Scientific Sessions of the American Diabetes Association to present Phase II clinical results of TOTUM-63 in prediabetes

Download
Release
13.05.2020

May 2020 Shareholders General Meeting (in French)

Download
Release
21.04.2020

VALBIOTIS publishes its annual results for 2019

Download
Release
16.04.2020

VALBIOTIS accelerates the clinical development of its pipeline in new indications: reducing cardiovascular risk and hepatic steatosis

Download
Release
07.04.2020

VALBIOTIS announces its 2020 financial communication calendar (in French)

Download
Release
02.04.2020

As part of a global partnership with Nestlé Health Science, VALBIOTIS initiates the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits in people with prediabetes

Download